A study on the effect of hemostatic agent and Kampo medicine (goreisan) for the clinical course of chronic subdural hematoma

DOI Web Site

Bibliographic Information

Other Title
  • 止血剤と利水剤が慢性硬膜下血腫に与える影響についての検討
  • シケツザイ ト リスイザイ ガ マンセイコウマク カケッシュ ニ アタエル エイキョウ ニ ツイテ ノ ケントウ

Search this article

Abstract

<p>In my personal experience, carbazochrome sodium sulfonate hydrate (Adona) and goreisan (TJ–17) had been used widely for the prevention to chronic sub­dural hematoma (cSDH) after minor head trauma, and the postoperative recurrence prevention. In this report, I tested the preventive effect to the reoperation of cSDH by using carbazochrome sodium sulfonate hydrate (Adona) and goreisan （TJ–17） in the recent decade. A total of 64 patients were included in this study. There were 43 males and 21 females, with an average age of 76.5 years. Eleven patients used antiplatelet agents, and 7 patients used warfarin potassium (Warfarin) before surgery. Only 2 patients needed the second surgery. There was no adverse effect by using carbazochrome sodium sulfonate hydrate (Adona) and goreisan (TJ–17). Average duration of carbazochrome sodium sul­fonate hydrate (Adona) and goreisan (TJ–17) usage was 60.1 days. Carbazochrome sodium sulfonate hydrate (Adona) and goreisan （TJ–17） therapy after the cSDH surgery has low reoperative rate (3.1%) and it has enough sufficient effect.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top